English español

Repositorio de la Universidad de Oviedo. > Producción Bibliográfica de UniOvi: RECOPILA > Artículos >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10651/28975

Title: Overexpression of proCOL11A1 as a stromal marker of breast cancer
Author(s): Fuentes Martínez, Nelson
García Pravia, María del Carmen
García Ocaña, Marcos
Menéndez Rodríguez, María Primitiva
Amo Iribarren, Jokin del
Suárez Fernández, Laura
Galván Hernández, José Alberto
Toyos González, Juan Ramón de los
Barneo Serra, Luis
Editors: Fuentes Martínez, Nelson
Keywords: Cáncer
Issue date: 2015
Publisher: http://www.hh.um.es
Citation: Histology and Histopathology, 30, p. 87-93 (2015)
Format extent: p. 87-93
Abstract: Background: Our previous studies demonstrated the expression of procollagen11A1 in fibroblasts of pancreatic cancer desmoplasia and the lack of expression in fibroblasts of pancreatitis by means of the polyclonal antibody (anti-proCOL11A1 pAb) we generated. In a similar way, we decided to compare the expression of procollagen11A1 in fibroblasts of infiltrating ductal carcinoma of the breast and fibroblasts of benign sclerosing lesions of the breast, in order to validate the anti-proCOL11A1 pAb in this setting and to study how proCOL11A1 expression relates to other prognostic and predictive factors, as well as to survival. Methods: 45 core biopsies of sclerosing adenosis and 50 core biopsies of infiltrating ductal carcinoma of the breast were stained with anti-proCOL11A1 pAb, a polyclonal antibody highly specific to the less homologous fraction of proCOL11A1 (in comparison with proCOL5A1 and proCOL11A2). In addition, the expression of the proCOL11A1 gene was measured by RT-qPCR. On the other hand, the expression of proCOL11A1 was compared to the expression of estrogenic receptors, progestagen receptors, the state of the epidermal growth factor receptor 2 (HER2), the histologic grade and the stage of the disease. We also compared the immunohistochemical expression of proCol11A1 to the disease-free interval, and to overall survival. Results: The immunohistochemical analysis showed that proCOL11A1 was expressed in 100% of infiltrating ductal carcinomas, but only focally expressed in 2.2% (1 case) of sclerosing adenosis, in agreement with RT-qPCR results. ProCOL11A1 expression did not prove to have a prognostic value in relation to the disease-free interval or to overall survival in infiltrating ductal carcinoma. Conclusion: The anti-proCOL11A1 pAb is a stromal marker for breast cancer and the expression of proCOL11A1 does not seem to have a prognostic value in infiltrating ductal carcinoma of the breast.
URI: http://hdl.handle.net/10651/28975
ISSN: 0213-3911
Sponsored: This research has been cofinanced by FEDER Funds from the European Union; Proyecto INNPACTO-ONCOPAN IPT-010000-2010-31; by Proyecto FISS-09-PS09/01911, Ministerio de Ciencia e Innovación, Spain; by Proyecto FC-11-PC10-23, FICYT, Eje 1 del Programa Marco Operativo FEDER del Principado de Asturias 2007-2013, Spain; and by Progenika Biopharma, S.A. and Oncomatrix, S.L. Derio, Spain. The proCOL11A1 mAb has been patented by Oncomatrix,S.L. (PCT/ES2012/070616; WO 2013/021088 A2).
Project id.: MICINN/IPT-010000-2010-31
Appears in Collections:Cirugía y Especialidades Médico Quirúrgicas
Investigaciones y Documentos OpenAIRE

Files in This Item:

File Description SizeFormat
Fuentes-Martinez-30-87-93-2015.pdfOverexpression of proCOL11A1 as a stromal marker of breast cancer1,19 MBAdobe PDFView/Open

Exportar a Mendeley

This item is licensed under a Creative Commons License
Creative Commons

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Base de Datos de Autoridades Biblioteca Universitaria Consultas / Sugerencias